HER2-Low Tumors — Deal Benchmarks & Valuation
Market Analysis
HER2-Low Tumors is one of the most actively transacted indications in oncology licensing. Phase 2 deals for her2-low tumors carry a median total deal value of $2.0B, with upfront payments ranging from $178M to $451M. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for her2-low tumors licensing?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating